title: MRI-guided focused ultrasound surgery for uterine fibroid treatment: a cost-effectiveness analysis.
abstract: OBJECTIVE. The purpose of this article is to evaluate the cost effectiveness of a treatment strategy for symptomatic uterine fibroids that uses MRI-guided focused ultrasound as a first-line therapy relative to uterine artery embolization (UAE) or hysterectomy. MATERIALS AND METHODS. We developed a decision-analytic model to compare the cost effectiveness of three first-line treatment strategies: MRI-guided focused ultrasound, UAE, and hysterectomy. Treatment-specific short- and long-term utilities, lifetime costs, and quality-adjusted life years (QALYs) were incorporated, allowing us to conduct an incremental cost-effectiveness analysis, using a societal willingness-to-pay (WTP) threshold of $50,000/QALY to designate a strategy as cost effective. Sensitivity analyses were subsequently performed on all key parameters. RESULTS. In the base-case analysis, UAE as a first-line treatment of symptomatic fibroids was the most effective and expensive strategy (22.75 QALYs; $22,968), followed by MRI-guided focused ultrasound (22.73 QALYs; $20,252) and hysterectomy (22.54 QALYs; $11,253). MRI-guided focused ultrasound was cost effective relative to hysterectomy, with an associated incremental cost-effectiveness ratio (ICER) of $47,891/QALY. The ICER of UAE relative to MRI-guided focused ultrasound was $234,565/QALY, exceeding the WTP threshold of $50,000/QALY, therefore rendering MRI-guided focused ultrasound also cost effective relative to UAE. In sensitivity analyses, results were robust to changes in most parameters but were sensitive to changes in probabilities of recurrence, symptom relief, and quality-of-life measures. CONCLUSION. First-line treatment of eligible women with MRI-guided focused ultra-sound is a cost-effective noninvasive strategy. For those not eligible for MRI-guided focused ultra-sound, UAE remains a cost-effective option. These recommendations integrate both the short- and long-term decrements in quality of life associated with the specific treatment modalities.
authors: 1 Department of Radiology, Massachusetts General Hospital, Institute for Technology Assessment, 101 Merrimac St, 10th Fl, Boston, MA 02114.
authors: Chung Y
authors: CY
authors: Kong
authors: Lesley
authors: L
authors: Meng
authors: Zehra B
authors: ZB
authors: Omer
authors: J Shannon
authors: JS
authors: Swan
authors: Serene
authors: S
authors: Srouji
authors: G Scott
authors: GS
authors: Gazelle
authors: Fiona M
authors: FM
authors: Fennessy
mesh_terms: D000328:Adult; D003362:Cost-Benefit Analysis; D017598:Efficiency, Organizational; D005260:Female; D006801:Humans; D007044:Hysterectomy / Q000191:economics; D007889:Leiomyoma / Q000191:economics / Q000628:therapy*; D053783:Magnetic Resonance Imaging, Interventional / Q000191:economics*; D018803:Models, Economic; D019057:Quality-Adjusted Life Years; D014464:Ultrasonic Therapy / Q000191:economics*; D014594:Uterine Neoplasms / Q000191:economics / Q000628:therapy*
keywords: MRI-guided focused ultrasound; cost effectiveness; hysterectomy; uterine fibroids